Evaluation of Minimal Residual Disease (MRD) By Next Generation Sequencing (NGS) Is Highly Predictive of Progression Free Survival in the IFM/DFCI 2009 Trial - Université de Rennes Access content directly
Journal Articles Blood Year : 2015

Evaluation of Minimal Residual Disease (MRD) By Next Generation Sequencing (NGS) Is Highly Predictive of Progression Free Survival in the IFM/DFCI 2009 Trial

Nelly Robillard
  • Function : Author
Laurent Garderet
Lionel Karlin
  • Function : Author
Frederique Orsini-Piocelle
  • Function : Author
Bruno Royer
  • Function : Author
Paul G. Richardson
  • Function : Author
Kenneth C. Anderson
  • Function : Author
Malek Faham
  • Function : Author
Philippe Moreau
Nikhil C Munshi
  • Function : Author

Abstract

57th Annual Meeting of the American-Society-of-Hematology Location: Orlando, FL Date: DEC 05-08, 2015
No file

Dates and versions

hal-01300806 , version 1 (11-04-2016)

Identifiers

Cite

Herve Avet-Loiseau, Jill Corre, Valérie Lauwers-Cances, Marie-Lorraine Chretien, Nelly Robillard, et al.. Evaluation of Minimal Residual Disease (MRD) By Next Generation Sequencing (NGS) Is Highly Predictive of Progression Free Survival in the IFM/DFCI 2009 Trial. Blood, 2015, 126 (23), pp.191. ⟨10.1182/blood.V126.23.191.191⟩. ⟨hal-01300806⟩
253 View
0 Download

Altmetric

Share

Gmail Facebook X LinkedIn More